4th Dec 2007 14:20
Lehman Brothers Intl (Europe)04 December 2007 Not for release or distribution, directly or indirectly, in or into the UnitedStates or any jurisdiction in which such release or distribution would beunlawful. GlaxoSmithKline Capital plc Stabilisation Notice Lehman Brothers International (Europe) (contact: Andre Portelli / Kevin White ;telephone: 020 7103 8398 / 020 7103 7933) hereby gives notice that theStabilising Managers named below may stabilise the offer of the followingsecurities in accordance with Commission Regulation (EC) No. 2273/2003 of 22December 2003 implementing the Market Abuse Directive (2003/6/EC). The securities: Issuer: GlaxoSmithKline Capital plcDescription:• 2,250,000,000 Fixed Rate Notes due 13 December 2012 &• 1,250,000,000 Fixed Rate Notes due 13 December 2017Offer price:2012 maturity : +85 basis points over the 5 year mid-swap rate2017 maturity : +115 basis points over the 10 year mid-swap rate Stabilisation: Stabilising Managers:Credit Suisse Securities (Europe) LimitedDeutsche Bank AG, London BranchLehman Brothers International (Europe)Stabilisation period expected to start on: 4 December 2007Stabilisation period expected to end no later than: 11 January 2008 (30 daysafter the proposed issue date of the securities)Maximum size of over-allotment facility: 5% of the aggregate nominal amountstated above Offering Circular: The Euro Medium Term Note Programme Offering Circular dated 9 March 2007 and theSecurities Note dated 4 December 2007 relating to these securities areavailable. The Securities Note should be read in conjunction with theRegistration Document dated 9 March 2007 and certain parts of the OfferingCircular dated 9 March 2007 which are incorporated by reference in theSecurities Note (together the "Securities Note"). In connection with the offer of the above securities, the Stabilising Managermay over-allot the securities or effect transactions with a view to supportingthe market price of the securities at a level higher than that which mightotherwise prevail. However, there is no assurance that the Stabilising Managerwill take any stabilisation action and any stabilisation action, if begun, maybe ended at any time. This announcement is for information purposes only and does not constitute aninvitation or offer to underwrite, subscribe for or otherwise acquire or disposeof any securities of the Issuer in any jurisdiction. To the extent that the offer of the securities is made in any EEA Member Statethat has implemented Directive 2003/71/EC (together with any applicableimplementing measures in any Member State, the "Prospectus Directive") beforethe date of publication of a prospectus in relation to the securities which hasbeen approved by the competent authority in that Member State in accordance withthe Prospectus Directive (or, where appropriate, published in another MemberState and notified to the competent authority in that Member State in accordancewith the Prospectus Directive), the offer is only addressed to qualifiedinvestors in that Member State within the meaning of the Prospectus Directive orhas been or will be made otherwise in circumstances that do not require theIssuer to publish a prospectus pursuant to the Prospectus Directive. This announcement is not an offer of securities for sale in the United States.The securities have not been, and will not be, registered under the UnitedStates Securities Act of 1933 and may not be offered or sold in the UnitedStates absent registration or an exemption from registration. There will be nopublic offer of securities in the United States. This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
Glaxosmithkline